Abstract: A new approach to targeting imaging agents to macrophage-rich sites of interest is disclosed. Compositions of the invention are rHDL and HDL-like liposomal compositions, protein constituents of which, apolipoproteins A-I and/or A-II or fragments thereof are used not only as structural but also as targeting agents. This is achieved by certain controlled chemical or enzymatic modification of apolipoproteins A-I or A-II or fragments thereof. Such modification converts these apolipoproteins to substrates for macrophage scavenger receptors and results in the improvement of contrast agent-(HDL/modified apolipoprotein)-particle association with macrophages and/or absorption (uptake) by macrophages when compared to that of the contrast agent-(HDL/apolipoprotein)-particle constructed with non-modified naturally occurring apo A-I.

Abstract: The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiopharmaceutical composition may be suitable for administration to a patient in need thereof, such as for the purpose of treating prostate cancer.

Abstract: A liver-targeted fluorescence/photoacoustic dual-modal probe for the early detection of drug-induced hepatic inflammation and autoimmune hepatitis is disclosed. The chemical makeup of the probe hCy-Tf-CA is shown in Equation 1. The fluorescence and photoacoustic signal of probe-only solution is very weak, the dual-modal signal was significantly increased after selectively reacting with . The probe has the advantages of early preparation, live-targeting ability, high selectivity and sensitivity and dual-modal imaging. The probe can in situ visualization of in early hepatic inflammation with fluorescent/photoacoustic dual-modal imaging, providing a potential strategy in biomedical field with broad application prospects.

Abstract: A graft or construct including an isolated cartilage chondrocytes from young donors (<20 years), seeded on a three-dimensional membrane composed of one of the main chondrogenesis-promoting substances (hyaluronic acid), in high densities (1×106) with autologous serum and sealed with a fibrin adhesive for the treatment of a cartilage lesion, with tissue formation that has greater durability, at a lower cost and with fewer risks than the treatments currently available for the management of such lesions. Likewise, a procedure for the treatment of articular cartilage lesions is provided, through the implantation of allogeneic chondrocyte grafts that present the capacity to generate or repair satisfactorily the cartilage of the lesion.

Abstract: Methods for treating a proliferative disease or disorder by administering an antibody radio-conjugate alone or in combination with an immune checkpoint therapy such as an antibody against an immune checkpoint inhibitor, and/or a DNA damage response inhibitor. The proliferative disease or disorder may be a solid cancer, such as breast cancer, ovarian cancer, or prostate cancer.

Abstract: The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiopharmaceutical composition may be suitable for administration to a patient in need thereof, such as for the purpose of treating prostate cancer.

Abstract: Provided herein, inter alia, are radionuclide-labeled antibodies, immunocytokines, and methods for treating cancer using combination therapy with the radionuclide-labeled antibodies and the immunocytokines.

Abstract: Provided in the present invention are a compound, a preparation method therefor, a composition, a kit, and the use thereof. The compound has a condensed structural formula as follows: wherein the cation M is selected from alkali metal cations, R is a C2-C5 alkyl, and n is an integer in the range of 2-5. The compound and an application product thereof have a good recognition ability and a good targeting performance for a PSMA receptor, can be widely applied to a plurality of scenarios such as flow cytometric analysis and in-vivo imaging in practical applications, and has the advantages of fast signal response speed, high resolution, good safety, excellent metabolic ability, etc.

Abstract: The disclosure relates to barcoded polymer nanoparticles for in vivo screening and for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, associated with polynucleotide barcodes, for therapeutic delivery, and for high throughput in vivo screening of drug delivery nanoparticles.

Abstract: A nanometric pharmaceutical composition in the form of liposomes or a nanoemulsion containing interference RNA strands comprising one or more of the following specific siRNA sequences: SEQ ID NO: 1; SEQ ID NO: 2; or SEQ ID NO: 3.

Abstract: Provided are compositions and methods for using the same. In some embodiments, the compositions include an EPELN encapsulating and/or having associated therewith an active agent and a plasma membrane derived from a tumor and/or cancer cell coating the EPELN. In some embodiments, the active agent is a therapeutic agent or an immune response modifier, and in some embodiments the plasma membrane has one or more tumor-associated and/or cancer-associated antigens. Also provided are methods for using the compositions for treating tumors and/or cancers, inducing anti-tumor and/or anti-cancer immune responses, activating antigen-presenting cells, targeting CD11c dendritic cells, and preventing or reducing metastasis.

Abstract: Described herein are chemoembolic compositions and agents. The compositions include one or more anti-cancer agents and a silk-elastinlike protein polymer, wherein the compositions are liquids prior to administration to a subject but convert to hydrogels upon administration to the subject. Administration of the Chemoembolic compositions to tumor and/or tumor vasculature in a subject having cancer can result in reduced or inhibited blood flow to the tumor as well as localized, sustained release of the anti-cancer agent in the vicinity of the tumor. Reduction in blood flow, in turn, results in a reduction of tumor volume and/or inhibition of tumor growth, while localized release of the anti-cancer agent results in reduced systemic effects and lower overall toxicity of treatment with the compositions.

Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.

Abstract: Silica nanorings, methods of making silica nanorings, and uses of silica nanorings. The silica nanorings may be PEGylated. The silica nanorings may be surface functionalized, which may be surface selective functionalization, with one or more polyethylene glycol (PEG) group(s), one or more display group(s), one or more functional group(s), or a combination thereof. The silica nanorings may have a size of 5 to 20 nm. The silica nanorings may be made using micelles. The absence or presence of the micelles during PEGylation and/or functionalization allows for surface selective functionalization. The silica nanorings may be used in various diagnostic and/or treatment methods.

Abstract: The present application is directed to a theranostic probe and its use for targeting and/or labeling the EGFR kinase and/or the cells expressing EGFR or its family members.

Abstract: The present disclosure provides a fluorescently-traceable amino acid derivative and a preparation method and use thereof, and belongs to the technical field of biomedicine. In the present disclosure, an amino acid skeleton of the amino acid derivative is modified mainly by a fluorescently-traceable functional group. 4-chloro-7-nitro-2,1,3-benzoxadiazole (NBD-Cl) has low polarity and strong fluorescence, and can be used to modify an N-terminal of the amino acid skeleton to conduct subcellular imaging. Moreover, the NBD-Cl has a relatively small volume, lacks reaction orthogonality, and causes little interference with biochemical reactions of the organism itself. The results of examples show that the fluorescently-traceable amino acid derivative has a desirable biological activity and can be fluorescently traced in vivo and in vitro.

Abstract: The invention relates to a surface gradient cross-linked method of a ultra-high molecular weight polyethylene and the application thereof. The surface gradient crosslinked method of ultrahigh molecular weight polyethylene includes a n ultra-high molecular weight polyethylene surface photoinitiator diffusion step and an ultraviolet light irradiation crosslinking step. In this method, the photoinitiator is diffused deeply into the surface of ultra-high molecular weight polyethylene, the body material shows a gradient cross-linking from the surface to the inside after ultraviolet irradiation so that the whole bulk has a high toughness and the surface there of has a high wear resistance.

Abstract: The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

Abstract: The present disclosure provides, inter alia, novel compounds targeting cholecystokinin-2 receptor (CCK2R) expressed on the surface of cancer cells. Also provided are methods for imaging, diagnosing, and/or treating cancers using the same.

Abstract: The present disclosure relates to a novel fluorogenic dimer compound, useful as a probe for detection of endogenous receptors, in particular G protein-coupled receptors. The present invention provides compositions and kits comprising such compound and methods of labeling a biomolecule, comprising the step of contacting the biomolecule with the compound of the invention.